Form 4: Milestone Pharmaceuticals Director Granted 40,000 Stock Options

Milestone Pharmaceuticals Inc. Director Michael John Tomsicek was granted 40,000 stock options with an exercise price of $1.75, vesting over 12 months.

Summary

• Milestone Pharmaceuticals Inc. (MIST) Director Michael John Tomsicek was granted 40,000 stock options.
• The options have an exercise price of $1.75 per share.
• The transaction date for the option grant was June 10, 2025.
• The options will vest in twelve equal monthly installments, beginning on July 10, 2025.
• The options will be fully vested by the date of the next annual meeting of stockholders, provided the director continues service.
• The expiration date for these options is June 10, 2035.

Sentiment

Score: 6

Explanation: Slightly positive. The grant of stock options to a director aligns interests with shareholders and indicates continued commitment, which is generally viewed favorably. However, it's a routine compensation event and not indicative of significant operational news.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term value creation.
• The continued equity compensation for Director Tomsicek indicates his ongoing commitment to the company.

Negatives

• No specific negative information was disclosed in this Form 4 filing.

Risks

• The value of the stock options is dependent on the future market price of Milestone Pharmaceuticals Inc. common stock exceeding the exercise price of $1.75.
• If the stock price does not rise above the exercise price, the options may expire worthless.

Future Outlook

The document indicates that the granted stock options will vest over the next twelve months, with full vesting by the next annual meeting, contingent on the director's continued service.

Management Comments

• The filing was signed by Jason Minio, Attorney-in-Fact for Michael John Tomsicek.

Industry Context

This filing represents a routine equity compensation event for a director in the pharmaceutical industry, a common practice to align executive incentives with shareholder value. It does not provide broader industry trends or competitive analysis.

Comparison to Industry Standards

• Granting stock options to directors is a standard practice across various industries, including pharmaceuticals, to incentivize long-term performance and retain key talent.
• The specific size of the grant (40,000 options) and the exercise price ($1.75) would typically be evaluated against peer company compensation packages and the company's overall compensation philosophy, though this document does not provide such comparative data.

Stakeholder Impact

• Shareholders: The grant of stock options to a director aims to align the director's financial interests with those of the shareholders, potentially leading to better long-term performance.
• Employees: No direct impact on general employees mentioned in this filing.

Next Steps

• The stock options will vest in twelve equal monthly installments, beginning July 10, 2025.
• The options will be fully vested on the date of the next annual meeting of stockholders, subject to continued service.

Key Dates

Keywords

Milestone Pharmaceuticals, MIST, Stock Options, Director Compensation, SEC Form 4, Insider Trading, Equity Grant, Beneficial Ownership